Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.

Due to the fact that only CALD1 showed significant association with the type of response, while ANXA1 displayed only borderline significance, combination of ANXA1 and CALD1 stainings was not performed using tumor response as the endpoint of tamoxifen therapy.

also in 7,017 other papers